• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Charles River Laboratories International Inc.

    5/7/26 4:56:54 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email
    S-8 1 dp246328_s8.htm FORM S-8

     

    Registration No. 333-   

     

    As filed with the Securities and Exchange Commission on May 7, 2026

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    CHARLES RIVER LABORATORIES
    INTERNATIONAL, INC.
    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   06-1397316
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    Charles River Laboratories International, Inc.
    2026 Long-Term Incentive Compensation Plan
    (Full title of the plan)

     

    Kerry Dailey
    Corporate Senior Vice President & Chief Legal Officer
    Charles River Laboratories International, Inc.
    251 Ballardvale Street
    Wilmington, MA 01887
    (Name and address of agent for service)

     

    (781) 222-6000
    (Telephone number, including area code, of agent for service)

     

    Copies to:
    Richard D. Truesdell, Jr.
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, New York 10017
    (212) 450-4000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☒ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☐
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Charles River Laboratories International Inc., a Delaware corporation (the “Registrant”), to register 4,825,000 shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”), available for issuance pursuant to the Charles River Laboratories International Inc. 2026 Long-Term Incentive Compensation Plan (the “Plan”).

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement and is included in documents sent or provided to participants of the Plan covered by this Registration Statement pursuant to Rule 428 of the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.        Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Securities and exchange Commission (the “SEC”) pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 27, 2025, filed with the SEC on February 18, 2026 (the “Annual Report”), including the sections of the Registrant’s Definitive Proxy Statement on Schedule 14A for the Registrant’s 2026 Annual Meeting of Shareholders, as filed with the Commission on March 31, 2026, incorporated by reference in the Annual Report;

     

    (b)The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on May 7, 2026;

     

    (c)The Registrant’s Current Reports on Form 8-K, filed with the SEC on January 9, 2026 and February 18, 2026;

     

    (d)All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

     

    (e)The description of the Registrant’s Common Stock contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 28, 2019, filed with the SEC on February 11, 2020, and any amendments and reports subsequently filed for the purposes of updating that description.

     

    In addition, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents with the SEC. The Registrant will not, however, incorporate by reference in this Registration Statement any documents or portions thereof that are not deemed “filed” with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of the Registrant’s Current Reports on Form 8-K unless, and except to the extent, specified in such Current Reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

    Item 4.        Description of Securities.

     

    Not applicable.

     

    Item 5.        Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.        Indemnification of Directors and Officers.

     

    Section 145 of the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Charles River Laboratories International, Inc.’s second amended and restated certificate of incorporation provides for indemnification by the registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law.

     

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for any breach of the director’s duty of loyalty to the corporation or its stockholders, for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, or for any transaction from which the director derived an improper personal benefit. The registrant’s second amended and restated certificate of incorporation provides for such limitation of liability.

     

    The registrant maintains standard policies of insurance under which coverage is provided to its directors and officers against loss rising from claims made by reason of breach of duty, misstatement, error or omission committed in their capacity as directors or officers of the registrant. Such policies of insurance also provide coverage to the registrant with respect to payments which may be made by the registrant to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

     

    Item 7.        Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

     

     

    Item 8.        Exhibits.

     

    Exhibit
    No.
      Description of Exhibit
         
    Exhibit 4.1   Second Amended and Restated Certificate of Incorporation of the Registrant, dated June 5, 2000 (incorporated by reference as Exhibit 3.1 to the Form S-1/A filed on June 23, 2000)
         
    Exhibit 4.2   Sixth Amended and Restated Bylaws of the Registrant, dated December 13, 2021 (incorporated by reference as Exhibit 3.1 to the Form 8-K filed on December 15, 2021)
         
    Exhibit 4.3   Form of the Registrant’s Common Stock Certificate (incorporated by reference as Exhibit 4.1 to the Form S-1/A filed on June 23, 2000)
         
    Exhibit 4.4   Description of Securities (incorporated by reference as Exhibit 4.2 to the Form 10-K filed on February 11, 2020)
         
    Exhibit 5.1*   Opinion of Davis Polk & Wardwell LLP
         
    Exhibit 23.1*   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
         
    Exhibit 23.2*   Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
         
    Exhibit 24.1*   Power of Attorney (included as part of the signature page to this Registration Statement)
         
    Exhibit 99.1*   Charles River Laboratories International, Inc. 2026 Long-Term Incentive Compensation Plan
         
    Exhibit 107*   Filing Fee Table

     

    * Filed herewith.

     

     

     

    Item 9.        Undertakings

     

    (a) The undersigned registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, in the Commonwealth of Massachusetts, on May 7, 2026.

     

      CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
         
      By: /s/ Birgit Girschick
       

    Birgit Girschick

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Charles River Laboratories International, Inc., hereby severally constitute and appoint Birgit Girshick and Kerry Dailey, and each of them singly, our true and lawful attorneys, with full power to sign for us in our names in the capacities indicated below, any amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in our capacities as officers and directors to enable Charles River Laboratories International, Inc. to comply with the provisions of the Securities Act of 1933, as amended, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on May 7, 2026.

     

    Name   Title(s)
         
    /s/ Birgit Girschick   Chief Executive Officer
    (Principal Executive Officer)
    Birgit Girschick
         
         
    /s/ Glenn Coleman   Corporate Executive Vice President &
    Glenn Coleman   Chief Financial Officer
    (Principal Financial Officer)
         
         
    /s/ Michael G. Knell   Corporate Senior Vice President &
    Michael G. Knell   Chief Accounting Officer
    (Principal Accounting Officer)
         
         
    /s/ Martin Mackay, Ph.D.   Chair
    Martin Mackay, Ph.D.    
         
         
    /s/ Nancy C. Andrews M.D., Ph.D.   Director
    Nancy C. Andrews M.D., Ph.D.
         
         
    /s/ Steven Barg   Director
    Steven Barg
         
         
    /s/ Abraham Ceesay   Director
    Abraham Ceesay
         
         
    /s/ James C. Foster   Director
    James C. Foster    
         
         
    /s/ Mark Enyedy   Director
    Mark Enyedy
         
         
    /s/ Paul Graves       Director
    Paul Graves    
         
         
    /s/ George Llado   Director
    George Llado    
         
         
    /s/ Craig B. Thompson M.D.   Director
    Craig B. Thompson M.D.    
         
         
    /s/ Virginia M. Wilson   Director
    Virginia M. Wilson    

     

     

     

    Get the next $CRL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    5/29/2026$219.00Hold → Outperform
    CLSA
    4/14/2026$215.00Outperform
    RBC Capital Mkts
    12/15/2025$225.00Neutral → Buy
    BofA Securities
    11/17/2025Hold → Buy
    Argus
    11/6/2025$199.00Neutral → Outperform
    Robert W. Baird
    10/6/2025Mkt Perform → Outperform
    William Blair
    10/2/2025$195.00Equal Weight → Overweight
    Barclays
    9/9/2025$195.00Hold → Buy
    Jefferies
    More analyst ratings

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charles River Laboratories to Present at William Blair and Jefferies Conferences

    Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 9:55 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for

    6/1/26 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions

    Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe. This press release

    5/13/26 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

    Charles River Laboratories International, Inc. (NYSE:CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is committed to cutting at least one week from standard pathology timelines while maintaining Good Laboratory Practice (GLP) rigor and regulatory readiness. These efficiency gains are driven by the combination of a fully integrated histology

    5/11/26 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Charles River upgraded by CLSA with a new price target

    CLSA upgraded Charles River from Hold to Outperform and set a new price target of $219.00

    5/29/26 8:03:56 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    RBC Capital Mkts initiated coverage on Charles River with a new price target

    RBC Capital Mkts initiated coverage of Charles River with a rating of Outperform and set a new price target of $215.00

    4/14/26 8:20:22 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by BofA Securities with a new price target

    BofA Securities upgraded Charles River from Neutral to Buy and set a new price target of $225.00

    12/15/25 9:01:39 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    SEC Filings

    View All

    Charles River Laboratories International Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    5/11/26 5:01:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-8 filed by Charles River Laboratories International Inc.

    S-8 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    5/7/26 4:56:54 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Charles River Laboratories International Inc.

    10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    5/7/26 4:14:22 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:39:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:41:25 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:38:37 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    6/3/26 9:45:20 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & Chief Financial Officer Coleman Glenn was granted 6,640 shares, increasing direct ownership by 31% to 27,752 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    6/2/26 4:46:05 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP, Chief Information Officer Mintz Mark was granted 2,534 shares and covered exercise/tax liability with 369 shares, increasing direct ownership by 29% to 9,546 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    6/2/26 4:42:55 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Leadership Updates

    Live Leadership Updates

    View All

    Charles River Laboratories Announces Executive Appointments

    Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre

    2/18/26 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

    – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

    5/7/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

    Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

    7/24/24 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Financials

    Live finance-specific insights

    View All

    Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2026 financial results on Thursday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate th

    4/16/26 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

    – Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm

    2/18/26 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi

    1/21/26 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Charles River Laboratories International Inc.

    SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    11/8/24 10:52:38 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    10/22/24 3:24:03 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    2/13/24 5:01:02 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care